We are live on ! Find out more
OMED

OncoMed Pharmaceuticals, Inc.
OMED

Delisted

OMED was delisted on the 22nd of April, 2019.

Back to rankings

83 hedge funds and large institutions have $235M invested in OncoMed Pharmaceuticals, Inc. in 2015 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 44 increasing their positions, 14 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

214% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 14

63% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 8

6% more funds holding

Funds holding: 78 → 83 (+5)

7% more call options, than puts

Call options by funds: $1.51M | Put options by funds: $1.41M

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

8% less capital invested

Capital invested by funds: $257M → $235M (-$21.5M)

Holders
83
Holders Change
+5
Holders Change %
+6.41%
% of All Funds
2.24%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
13
Increased
44
Reduced
14
Closed
8
Calls
$1.51M
Puts
$1.41M
Net Calls
+$97K
Net Calls Change
-$103K

Top Buyers

Rank Fund Capital Flow
1
CC
Cannell & Co
New York
+$3.36M
2
BFA
BlackRock Fund Advisors
California
+$2.47M
3
IHM
Iguana Healthcare Management
New York
+$2.47M
4
AC
Apex Capital
California
+$1.56M
5
N
Nuveen
North Carolina
+$1.04M

Top Sellers

Rank Fund Capital Flow
1
SAM
Sectoral Asset Management
Quebec, Canada
-$4.05M
2
American Century Companies
American Century Companies
Missouri
-$1.65M
3
SGAM
Smith Group Asset Management
Texas
-$1.26M
4
CS
Candriam SCA
Luxembourg
-$986K
5
BI
BVF Inc
California
-$478K
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
26
Candriam SCA
Luxembourg
$1.8M -$986K -40,000 -33%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$1.62M +$414K +16,802 +30%
Mitsubishi UFJ Asset Management
28
Mitsubishi UFJ Asset Management
Japan
$1.57M +$372K +15,100 +28%
QI
29
QS Investors
New York
$1.49M +$241K +9,770 +17%
BIM
30
BlackRock Investment Management
Delaware
$1.35M +$569K +23,087 +63%
BC
31
Birchview Capital
Vermont
$1.32M +$345K +14,000 +31%
Deutsche Bank
32
Deutsche Bank
Germany
$1.17M +$234K +9,486 +22%
HLA
33
Hamilton Lane Advisors
Pennsylvania
$989K +$250K +10,120 +30%
TAM
34
Tocqueville Asset Management
New York
$928K -$51.8K -2,100 -5%
Charles Schwab
35
Charles Schwab
California
$859K +$174K +7,066 +23%
PI
36
Putnam Investments
Massachusetts
$850K -$7.32K -297 -0.8%
TC
37
TFS Capital
Pennsylvania
$777K +$852K +34,548 New
California State Teachers Retirement System (CalSTRS)
38
California State Teachers Retirement System (CalSTRS)
California
$695K +$194K +7,857 +34%
AA
39
ALPS Advisors
Colorado
$670K +$369K +14,958 +101%
GT
40
Glenmede Trust
Pennsylvania
$645K – – –
ProShare Advisors
41
ProShare Advisors
Maryland
$588K -$8.85K -359 -1%
HCM
42
Hodges Capital Management
Texas
$562K +$123K +5,000 +25%
Renaissance Technologies
43
Renaissance Technologies
New York
$561K +$615K +24,942 New
TA
44
Teachers Advisors
New York
$547K +$165K +6,684 +38%
PCM
45
Piermont Capital Management
Missouri
$506K +$555K +22,500 New
BAM
46
Brave Asset Management
New Jersey
$476K – – –
AWCI
47
Alpine Woods Capital Investors
New York
$450K +$493K +20,000 New
SO
48
STRS Ohio
Ohio
$447K -$192K -7,800 -28%
Wells Fargo
49
Wells Fargo
California
$420K +$443K +17,975 +2,616%
Susquehanna International Group
50
Susquehanna International Group
Pennsylvania
$387K -$351K -14,219 -45%
1
2
3 4

OMED Hedge Fund Activity: Q2 2015 in Review

83 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q2 2015, worth a combined $235M — down 8.4% from $257M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new OMED positions and 8 closed out — a net gain of 5 holders — while 44 added to existing stakes and 14 trimmed.

The largest buyer was Cannell & Co, adding an estimated $3.36M. The largest seller was Sectoral Asset Management, cutting an estimated $4.05M.

  • 83 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q2 2015, up from 78 in Q1 2015.
  • Funds reported $235M of OncoMed Pharmaceuticals, Inc. stock for Q2 2015, down 8.4% quarter-over-quarter.
  • 13 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q2 2015 and 8 closed out, a net change of +5 holders.
  • The largest OncoMed Pharmaceuticals, Inc. buyer in Q2 2015 was Cannell & Co, an estimated $3.36M added.
  • The largest OncoMed Pharmaceuticals, Inc. seller in Q2 2015 was Sectoral Asset Management, an estimated $4.05M sold.

Based on aggregated 13F filings for Q2 2015.